Dr. Jeffrey L. Cummings

Headshot of Jeffrey L. Cummings
Download High-Res Photo
Request as Speaker
Request as Media Expert
Research Professor, Department of Brain Health
Director, Chambers-Grundy Center for Transformative Neuroscience at UNLV
Expertise: Neuroscience, neurodegenerative diseases, Alzheimer’s Disease, drug development, clinical trials, neurotherapeutics

Biography

Jeffrey L. Cummings, MD, ScD, joined the UNLV School of Integrated Health Sciences in 2019 as research professor within the department of brain health. Dr. Cummings is the Joy Chambers-Grundy Professor of Brain Science, an endowed professorship. He is the Director of the Chambers-Grundy Center for Transformative Neuroscience, a center devoted to using the tools of neuroscience and neurologic drug development to transform people’s lives.

Prior to UNLV, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, and as director of the Mary S. Easton Center for Alzheimer’s Disease Research, and director of the Deane F. Johnson Center for Neurotherapeutics, both at UCLA.

A world-renowned Alzheimer’s researcher and leader of clinical trials, Dr. Cummings has been recognized for his scientific and leadership contributions with the American Geriatrics Society’s Henderson Award (2006), the national Alzheimer’s Association’s Ronald and Nancy Reagan Research Award (2008), the American Association of Geriatric Psychiatry’s Distinguished Scientist Award (2010), and the Melvin R. Goodes Prize from the the Alzheimer's Drug Discovery Foundation (2019).

Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. Dr. Cummings has published nearly 800 articles and 44 books devoted to neuroscience, Alzheimer’s disease, and clinical trials.

Dr. Cummings received the Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award (2017), the International Society of CNS Drug Development’s Leadership and Achievement Award and the national Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award (2018).

Additionally, he was featured in Gentleman’s Quarterly (June 2009) as a “Rock Star of Science. ™” In addition to his work at UNLV, Dr. Cummings is professor of medicine (Neurology) at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, and he is principal investigator/director of the National Institute of General Medical Sciences-funded Center for Neurodegeneration and Translational Neuroscience.

Education

  • Sc.D., Science, University of Wyoming
  • Neurology fellowship, Boston University School of Medicine
  • Neuropathology/Neuropsychiatry fellowship, National Hospital for Nervous Diseases, London
  • M.D., Medicine, University of Washington
  • B.S., Zoology/Philosophy, University of Wyoming

Search For Other Experts On

health & medicine, science & technology

Dr. Jeffrey L. Cummings In The News

FDA authorizes AI-driven MRI Solution for Safer Alzheimer’s Treatment
Imaging Technology News
On Nov. 7, 2024, the U.S. Food and Drug Administration (FDA) granted icometrix clearance for icobrain aria, the first AI software approved for detecting, measuring and grading amyloid-related imaging abnormalities (ARIA), a potentially harmful side effect of new amyloid-targeting therapies. A large study, needed for FDA clearance, demonstrated that the use of icobrain aria significantly increases the accuracy of ARIA assessments by radiologists and hence allows for safer use of new amyloid-beta targeting therapies for Alzheimer’s disease patients.
T-Neuro Pharma Welcomes Renowned Alzheimer's Researcher Dr. Jeffrey Cummings as Chair of Scientific Advisory Board
PR Newswire
T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, announced today the appointment of Dr. Jeffrey Cummings, MD, ScD as Chair of its Scientific Advisory Board (SAB). Dr. Cummings, a world-renowned expert in Alzheimer's disease research and clinical trials, brings unparalleled expertise to T-Neuro Pharma's mission of advancing early Alzheimer's detection.
Alzheimer's Progression May Be Slowed by Targeted Magnetic Pulses, Study Suggests
MedPage Today
Investigational transcranial magnetic stimulation that targeted a brain network involved in memory slowed progression in mild-to-moderate Alzheimer's disease, data from a small phase II study suggested.
Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
Globe NewsWire
Praxis Bioresearch reports that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for PRX-P4-003, a gut-activated stimulant, to treat apathy in Alzheimer’s Disease. Previously, an exploratory microdose clinical trial in healthy volunteers demonstrated successful activation of PRX-P4-003 upon oral administration, the intended therapeutic route.
All Dr. Jeffrey L. Cummings In The News

Articles Featuring Dr. Jeffrey L. Cummings

UNLV Newsmakers 2024: May and June
Josh Hawkins, UNLV
Campus News | July 3, 2024

News highlights featuring UNLV students and staff who made (refreshing) waves in the headlines.

UNLV Newsmakers 2024: April
students in spring
Campus News | May 1, 2024

News highlights starring UNLV students and faculty who made local and national headlines.

All Articles Featuring Dr. Jeffrey L. Cummings